Advertisement

Diminished D2 Dopamine Receptor Function and the Emergence of Repetitive Jaw Movements

  • H. Rosengarten
  • J. W. Schweitzer
  • M. Egawa
  • A. J. Friedhoff
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 235)

Abstract

Oral movements in rats, repetitive jaw movements (RJM), can be induced in a dose dependent manner by a specific D1 agonist, SKF 38393, and decreased by D2 receptor stimulation with a specific D2 agonist, LY 141865. Irreversible D1 receptor inactivation by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline severely reduced oral responses induced by SKF 38393, whereas such blockade of D2 receptors greatly augmented the D1 mediated behavior. Further, we found that chronic prolonged D1 receptor blockade following administration of fluphenazine decanoate facilitated repetitive jaw movements.

Keywords

Tardive Dyskinesia Neuroleptic Treatment Fluphenazine Decanoate Receptor Supersensitivity Oral Movement 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Burt, D.R., Creese, I, and Snyder, S.H., 1977, Antischizophrenic drugs: Chronic treatment elevates dopamine receptor binding in brain, Science 196: 326.CrossRefGoogle Scholar
  2. Clow, A., Jenner, P. and Marsden, C.D., 1979, Changes in dopamine-mediated behavior during one year’s neuroleptic administration, Eur. J. Pharmacol. 29: 365.CrossRefGoogle Scholar
  3. Costali, B. and Naylor, R.J., 1974, Stereotyped behavior induced by dopaminergic agonists after lesion of the midbrain raphae nuclei, Eur. J. Pharmacol. 29: 206.CrossRefGoogle Scholar
  4. Ellison, G., See, R., Levin, E. and Kinney, J., 1987, Tremorous mouth movements in rats administered chronic neuroleptics, Psychopharm. 92: 122.CrossRefGoogle Scholar
  5. Farde, L., Halldin, C., Stone-Elander, S., and Sedvall, G., 1987, PET analysis of human dopamine receptor subtypes using 11CSCH 23390 and 11C-raclopride, Psychopharm. 92: 278.CrossRefGoogle Scholar
  6. Friedhoff, A.J., Bonnet, K.A. and Rosengarten, H., 1977, Reversal of two manifestations of dopamine receptor supersensitivity by administration of L-dopa, Res. Commun. Chem. Pathol. Pharmacol. 16: 887.Google Scholar
  7. Gianutsos, G., Drawbaugh, R.B., Haynes, M.D. and Lal, H., 1974, Behavioral evidence for dopaminergic supersensitivity after chronic haloperidol, Life Sci. 14: 887.CrossRefGoogle Scholar
  8. Hyttel, J., Larsen, J.JH., Christensen, A.V. and Arnt, J., 1985, Receptor binding profile in Dyskinesia-Research and Treatment, Psychopharm. Suppl. 2: 9.Google Scholar
  9. Meller, E. and Friedman, E., 1980, Striatal dopaminergic activity during withdrawal from chronic neuroleptic treatment in rats, in: “Tardive Dyskinesia”, Fann, W.E., Smith, R.C., Davis, J.M. and Domino, E.F., eds., Spectrum Publications, New York.Google Scholar
  10. Meller, E., Bohmaker, K., Goldstein, M. and Friedhoff, A.J., 1985, Inactivation of D1 and D2 dopamne receptors by N-ethoxycarbonyl-2-ethoxy-1, 2-dihydroquinolihe in vivo: Selective protection by neuroleptics, .J. Pharmacol. Exp. Ther. 333: 656.Google Scholar
  11. Molloy, A.G. and Waddington, J.L., 1984, Dopaminergic behavior stereotypically promoted by D1 agonist R-SK&F 38393 and selectively blocked by the D1 antagonist SCH 23390, Psychopharm. 82: 409.CrossRefGoogle Scholar
  12. Muller, P. and Seernan, P., 1976, Alterations in dopaminergic sensitivity in chronically pretreated rats, Soc. Neurosci., Abstr. 2: 874.Google Scholar
  13. Muller, P. and Seeman, P., 1977, Brain neurotransmitter receptors after long term haloperidol: Dopamine, acetylcholine, serotonine, — noradrenergic and naloxone receptors, Life Sci. 21: 1751.CrossRefGoogle Scholar
  14. Rosengarten, H., Schweitzer, J.W. and Friedhoff, A.J., 1983, Induction of oral dyskinesias in naive rats by D1 stimulation, Life Sci. 33: 2479.CrossRefGoogle Scholar
  15. Rosengarten, H., Schweitzer, J.W. and Friedhoff, A.J., 1986, Selective dopamine D2 receptor reduction enhances a D1 mediated oral dyskinesia in rats, Life Sci. 39: 29.CrossRefGoogle Scholar
  16. Sahakian, B.J., Robbins, T.W. and Iversen, S.D., 1976, Flupenthixol-induced hyperactivity by chronic dosing in rats, Eur. J. Pharmacol. 37: 169.CrossRefGoogle Scholar
  17. Sailer, F.C. and Salama, A., 1986, D1 and D2 dopamine receptor blockade: interactive effects in vitro and in vivo, J. Pharmacol. Exp. Ther. 236: 714.Google Scholar
  18. Stoof, J.C. and Kebabian, J.W., 1981, Opposing roles for the D1 and D2 dopamine receptors in efflux of cyclic AMP from rat neostriatum, Science 294: 366.Google Scholar
  19. Tarsy, D. and Baldessarini, R.J., 1974, Behavioral supersensitivity to apomorphine following chronic treatment with drugs which interfere with synaptic function of catecholamines, Neuropharmacology 13: 927.CrossRefGoogle Scholar
  20. Waddington, J.L. and Gamble, S.T., 1980, Neuroleptic treatment for a substantial proportion of adult life: Behavioral sequelae of 9 months haloperidol administration, Eur. J. Pharmacol. 67: 363.CrossRefGoogle Scholar
  21. Waddington, J.L., Cross, A.J., Gamble, S.T. and Bourne, R.C., 1983a, Spontaneous orofacial dyskinesia and dopaminergic function in rats after 6 months of neuroleptic treatment, Science 220: 530.CrossRefGoogle Scholar
  22. Waddington, J.L., Gross, A.J., Gamble, S.T. and Bourne, R.C., 1983b, Dopamine receptor function and spontaneous orofacial dyskinesia in rats during 6-month neuroleptic treatments, Adv. Biochem. Psychopharmacol. 37: 299.Google Scholar
  23. Weiss, B., Santelli, S. and Tusink, G., 1977, Movement disorders induced in monkeys by chronic haloperidol treatment, Psychopharm. 53: 289.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1988

Authors and Affiliations

  • H. Rosengarten
    • 1
  • J. W. Schweitzer
    • 1
  • M. Egawa
    • 1
  • A. J. Friedhoff
    • 1
  1. 1.Millhauser Laboratories, Department of PsychiatryNew York University School of MedicineNew YorkUSA

Personalised recommendations